{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:39:43Z","timestamp":1788230383499,"version":"build-2803163510"},"reference-count":21,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:p>MT-3724, a novel engineered toxin body comprised of an anti-CD20 single-chain variable fragment genetically fused to Shiga-like Toxin A subunit, is capable of binding to and internalizing against CD20, inducing cell killing via permanent ribosomal inactivation. This study evaluated MT-3724 in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (r\/rNHL). This open-label, multiple-dose phase Ia\/b trial included a dose escalation in patients with r\/rNHL according to a standard 3+3 design. Primary objectives were to determine the MTD and pharmacokinetics\/pharmacodynamics. In a dose expansion study at MTD in serum rituximab-negative patients with diffuse large B-cell lymphoma (DLBCL), primary objectives were safety, tolerability, and pharmacokinetics\/pharmacodynamics. Twenty-seven patients enrolled. MTD was 50 \u03bcg\/kg\/dose with 6,000 \u03bcg\/dose cap. Thirteen patients experienced at least one grade \u22653 treatment-related adverse events; the most common grade \u22653 event was myalgia (11.1%). Two patients (75 \u03bcg\/kg\/dose) experienced grade 2 treatment-related capillary leak syndrome. Overall objective response rate was 21.7%. In serum rituximab-negative patients with DLBCL or composite DLBCL (n = 12), overall response rate was 41.7% (complete response, n = 2; partial response, n = 3). In patients with detectable baseline peripheral B cells, treatment resulted in dose-dependent B-cell depletion. The proportion of patients with anti-drug antibodies (ADA) increased during treatment and the majority appeared to be neutralizing based on an in vitro assay; nevertheless, tumor regression and responses were observed. MT-3724 demonstrated efficacy at the MTD in this population of previously treated patients with r\/rDLBCL, with mild-to-moderate immunogenic safety events.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This work describes the safety and efficacy of a new pharmaceutical pathway that could provide a treatment option for a subset of patients with a critical unmet therapeutic need. The study drug, MT-3724, is capable of targeting B-cell lymphomas via a unique, potent cell-killing mechanism that appears to be promising.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0056","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T10:27:40Z","timestamp":1650623260000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-1804","authenticated-orcid":true,"given":"Paul A.","family":"Hamlin","sequence":"first","affiliation":[{"name":"1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9471-7170","authenticated-orcid":true,"given":"Vasile","family":"Musteata","sequence":"additional","affiliation":[{"name":"2Institute of Oncology, ARENSIA EM, Chisinau, Republic of Moldova."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven I.","family":"Park","sequence":"additional","affiliation":[{"name":"3Levine Cancer Institute, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Burnett","sequence":"additional","affiliation":[{"name":"4Molecular Templates, Inc., Jersey City, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Dabovic","sequence":"additional","affiliation":[{"name":"4Molecular Templates, Inc., Jersey City, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-2274","authenticated-orcid":true,"given":"Thomas","family":"Strack","sequence":"additional","affiliation":[{"name":"4Molecular Templates, Inc., Jersey City, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-4230","authenticated-orcid":true,"given":"Eric T.","family":"Williams","sequence":"additional","affiliation":[{"name":"5Molecular Templates, Austin, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banmeet S.","family":"Anand","sequence":"additional","affiliation":[{"name":"5Molecular Templates, Austin, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack P.","family":"Higgins","sequence":"additional","affiliation":[{"name":"5Molecular Templates, Austin, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-2142","authenticated-orcid":true,"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[{"name":"6University of Arizona Cancer Center, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"2023030220215955100_","article-title":"Getting the facts. Diffuse large B-cell lymphoma","author":"Lymphoma Research Foundation","year":"2018"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/10428190500085024","article-title":"The adverse prognostic impact of advanced age in multiple myeloma","volume":"46","author":"Mileshkin","year":"2005","journal-title":"Leuk Lymphom"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"key":"2023030220215955100_","first-page":"331","article-title":"CD20 expression and effects on outcome of relapsed\/refractory diffuse large B cell lymphoma after treatment with rituximab","volume":"19","author":"Rasheed","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-018-0066-7","article-title":"The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma","volume":"8","author":"Huang","year":"2018","journal-title":"Blood Cancer J"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood.V122.21.5152.5152","article-title":"CD20-specific engineered toxin body demonstrates direct cell kill of multiple B-cell non-Hodgkin's Lymphoma types","volume":"122","author":"Rajagopalan","year":"2013","journal-title":"Blood"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1538-7445.AM2016-1483","article-title":"MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin's lymphoma [abstract]","volume":"76","author":"Robinson","year":"2016","journal-title":"Cancer Res"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1016\/S0021-9258(19)68905-2","article-title":"Subunit structure of Shigella cytotoxin","volume":"256","author":"Olsnes","year":"1981","journal-title":"J Biol Chem"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023030220215955100_","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","article-title":"Critical issues in the development of immunotoxins for anticancer therapy","volume":"109","author":"Kim","year":"2020","journal-title":"J Pharm Sci"},{"key":"2023030220215955100_","volume-title":"ONTAK\u00ae (denileukin diftitox) solution for Intravenous use [prescribing information]","year":"2008"},{"key":"2023030220215955100_","volume-title":"LUMOXITI\u2122 (moxetumomab pasudotox-tdfk) for injection, for intravenous use [prescribing information]","year":"2020"},{"key":"2023030220215955100_","volume-title":"ELZONRIS (tagraxofusp-erzs) injection, for intravenous use","year":"2018"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0056\/3117670\/crc-22-0056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/307\/3279553\/crc-22-0056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/5\/307\/3279553\/crc-22-0056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:46:14Z","timestamp":1700462774000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/5\/307\/696295\/Safety-and-Efficacy-of-Engineered-Toxin-Body-MT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0056","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550680.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544535.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550680","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}